Rein Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	4.45	3.22	12.87	17.34	5.22	3.63
Short-Term Investments	-	-	-	-	16.05	42.33
Cash & Short-Term Investments	4.45	3.22	12.87	17.34	21.27	45.96
Cash Growth	-40.16%	-75.01%	-25.80%	-18.48%	-53.73%	219.20%
Other Current Assets	1.01	1.11	0.79	0.88	0.61	2.22
Total Current Assets	5.45	4.33	13.66	18.27	21.87	48.18
Net Property, Plant & Equipment	-	-	0	0.07	0.11	0.28
Other Intangible Assets	13.5	13.5	42.2	79.2	-	-
Goodwill	6.33	6.33	6.33	6.33	-	-
Other Long-Term Assets	1.01	0	0	2.19	0.02	0.02
Total Assets	26.29	24.16	62.19	106.01	22.01	48.48
Accounts Payable	6.26	3.98	0.91	1.19	1.72	1.21
Accrued Expenses	2.45	2.2	4.84	3.15	1.63	3.21
Short-Term Debt	4.92	-	-	-	-	-
Current Portion of Leases	-	-	-	0.05	0.03	0.09
Total Current Liabilities	13.64	6.18	5.75	4.39	3.38	4.51
Long-Term Leases	-	-	-	-	-	0.07
Other Long-Term Liabilities	1.06	1.06	2.05	3.33	-	-
Total Long-Term Liabilities	1.06	1.06	2.05	3.33	-	0.07
Total Liabilities	14.7	7.24	7.8	7.71	3.38	4.58
Shareholders' Equity	11.59	16.92	54.39	98.3	18.62	43.9
Total Liabilities & Equity	26.29	24.16	62.19	106.01	22.01	48.48
Total Debt	4.92	0	0	0.05	0.03	0.16
Net Cash (Debt)	-0.48	3.22	12.87	17.29	21.23	45.8
Net Cash Growth	-	-75.01%	-25.59%	-18.57%	-53.63%	226.86%
Net Cash Per Share	-0.02	0.13	0.72	3.76	4.68	10.31
Tangible Book Value	-19.83	-19.83	-48.53	-85.53	0	0
Tangible Book Value Per Share	-0.72	-0.78	-2.71	-18.60	-	-

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q